A definitive diagnosis of MADD is established through the identification of elevated levels of several acylcarnitine species in blood, along with increased excretion of multiple organic acids in urine, and through the detection of biallelic pathogenic variants in the ETFA, ETFB, or ETFDH genes. Here, ETFDH is linked to multiple acyl-CoA dehydrogenase deficiency.